Physician profile
Michael N Kiselow
NPI 1881673184
$2,833.68
in general payments reported to CMS, 2019-2025
14 companies · $55.16 in 2025
The $55.16 reported for 2025 was less than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $233 · 2021: $267 · 2022: $667 · 2023: $313 · 2024: $660 · 2025: $55.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $737.05 | 2023-2024 | Miebo, Infuse, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $586.45 | 2019-2021 | |
| Glaukos Corporation | $294.23 | 2022-2023 | |
| Oyster Point Pharma, INC. | $207.28 | 2022 | |
| Sight Sciences, INC. | $192.39 | 2022 | |
| Oculus, INC. | $155.77 | 2019 | |
| Shire North American Group INC | $126.68 | 2019 | |
| Allergan, INC. | $123.08 | 2022 | |
| Sun Pharmaceutical Industries INC. | $118.31 | 2021 | |
| Aerie Pharmaceuticals, INC. | $106.70 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $106.04 | 2021-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $37.94 | 2022 | |
| Abbvie INC. | $21.16 | 2024 | |
| Alcon Vision LLC | $20.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kiselow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.